1
|
Zhuang M, Li X, Qiu Z, Guan J. Does consensus contour improve robustness and accuracy in 18F-FDG PET radiomic features? EJNMMI Phys 2024; 11:48. [PMID: 38839641 PMCID: PMC11153434 DOI: 10.1186/s40658-024-00652-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Accepted: 05/30/2024] [Indexed: 06/07/2024] Open
Abstract
PURPOSE The purpose of our study is to validate the robustness and accuracy of consensus contour in 2-deoxy-2-[18 F]fluoro-D-glucose (18 F-FDG) PET radiomic features. METHODS 225 nasopharyngeal carcinoma (NPC) and 13 extended cardio-torso (XCAT) simulated data were enrolled. All segmentation were performed with four segmentation methods under two different initial masks, respectively. Consensus contour (ConSeg) was then developed using the majority vote rule. 107 radiomic features were extracted by Pyradiomics based on segmentation and the intraclass correlation coefficient (ICC) was calculated for each feature between masks or among segmentation, respectively. In XCAT ICC between segmentation and simulated ground truth were also calculated to access the accuracy. RESULTS ICC varied with the dataset, segmentation method, initial mask and feature type. ConSeg presented higher ICC for radiomic features in robustness tests and similar ICC in accuracy tests, compared with the average of four segmentation results. Higher ICC were also generally observed in irregular initial masks compared with rectangular masks in both robustness and accuracy tests. Furthermore, 19 features (17.76%) had ICC ≥ 0.75 in both robustness and accuracy tests for any of the segmentation methods or initial masks. The dataset was observed to have a large impact on the correlation relationships between radiomic features, but not the segmentation method or initial mask. CONCLUSIONS The consensus contour combined with irregular initial mask could improve the robustness and accuracy in radiomic analysis to some extent. The correlation relationships between radiomic features and feature clusters largely depended on the dataset, but not segmentation method or initial mask.
Collapse
Affiliation(s)
- Mingzan Zhuang
- Department of Nuclear Medicine, Meizhou People's Hospital, Meizhou, China.
- Guangdong Engineering Technological Research Center of Clinical Molecular Diagnosis and Antibody Drugs, Meizhou People's Hospital, Meizhou, China.
| | - Xianru Li
- Department of Nuclear Medicine, Meizhou People's Hospital, Meizhou, China
| | - Zhifen Qiu
- Department of Nuclear Medicine, Meizhou People's Hospital, Meizhou, China
| | - Jitian Guan
- Department of Radiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
| |
Collapse
|
2
|
Zhao H, Su Y, Wang Y, Lyu Z, Xu P, Gu W, Tian L, Fu P. Using tumor habitat-derived radiomic analysis during pretreatment 18F-FDG PET for predicting KRAS/NRAS/BRAF mutations in colorectal cancer. Cancer Imaging 2024; 24:26. [PMID: 38342905 PMCID: PMC10860234 DOI: 10.1186/s40644-024-00670-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 01/29/2024] [Indexed: 02/13/2024] Open
Abstract
BACKGROUND To investigate the association between Kirsten rat sarcoma viral oncogene homolog (KRAS) / neuroblastoma rat sarcoma viral oncogene homolog (NRAS) /v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations and the tumor habitat-derived radiomic features obtained during pretreatment 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with colorectal cancer (CRC). METHODS We retrospectively enrolled 62 patients with CRC who had undergone 18F-FDG PET/computed tomography from January 2017 to July 2022 before the initiation of therapy. The patients were randomly split into training and validation cohorts with a ratio of 6:4. The whole tumor region radiomic features, habitat-derived radiomic features, and metabolic parameters were extracted from 18F-FDG PET images. After reducing the feature dimension and selecting meaningful features, we constructed a hierarchical model of KRAS/NRAS/BRAF mutations by using the support vector machine. The convergence of the model was evaluated by using learning curve, and its performance was assessed based on the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis. The SHapley Additive exPlanation was used to interpret the contributions of various features to predictions of the model. RESULTS The model constructed by using habitat-derived radiomic features had adequate predictive power with respect to KRAS/NRAS/BRAF mutations, with an AUC of 0.759 (95% CI: 0.585-0.909) on the training cohort and that of 0.701 (95% CI: 0.468-0.916) on the validation cohort. The model exhibited good convergence, suitable calibration, and clinical application value. The results of the SHapley Additive explanation showed that the peritumoral habitat and a high_metabolism habitat had the greatest impact on predictions of the model. No meaningful whole tumor region radiomic features or metabolic parameters were retained during feature selection. CONCLUSION The habitat-derived radiomic features were found to be helpful in stratifying the status of KRAS/NRAS/BRAF in CRC patients. The approach proposed here has significant implications for adjuvant treatment decisions in patients with CRC, and needs to be further validated on a larger prospective cohort.
Collapse
Affiliation(s)
- Hongyue Zhao
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Yexin Su
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Yan Wang
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Zhehao Lyu
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Peng Xu
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Wenchao Gu
- Department of Diagnostic and Interventional Radiology, University of Tsukuba, Ibaraki, Japan
| | - Lin Tian
- Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
| | - Peng Fu
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
| |
Collapse
|
3
|
Carlier T, Frécon G, Mateus D, Rizkallah M, Kraeber-Bodéré F, Kanoun S, Blanc-Durand P, Itti E, Le Gouill S, Casasnovas RO, Bodet-Milin C, Bailly C. Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study. J Nucl Med 2024; 65:156-162. [PMID: 37945379 DOI: 10.2967/jnumed.123.265872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 10/17/2023] [Indexed: 11/12/2023] Open
Abstract
The results of the GA in Newly Diagnosed Diffuse Large B-Cell Lymphoma (GAINED) study demonstrated the success of an 18F-FDG PET-driven approach to allow early identification-for intensification therapy-of diffuse large B-cell lymphoma patients with a high risk of relapse. Besides, some works have reported the prognostic value of baseline PET radiomics features (RFs). This work investigated the added value of such biomarkers on survival of patients involved in the GAINED protocol. Methods: Conventional PET features and RFs were computed from 18F-FDG PET at baseline and extracted using different volume definitions (patient level, largest lesion, and hottest lesion). Clinical features and the consolidation treatment information were also considered in the model. Two machine-learning pipelines were trained with 80% of patients and tested on the remaining 20%. The training was repeated 100 times to highlight the test set variability. For the 2-y progression-free survival (PFS) outcome, the pipeline included a data augmentation and an elastic net logistic regression model. Results for different feature groups were compared using the mean area under the curve (AUC). For the survival outcome, the pipeline included a Cox univariate model to select the features. Then, the model included a split between high- and low-risk patients using the median of a regression score based on the coefficients of a penalized Cox multivariate approach. The log-rank test P values over the 100 loops were compared with a Wilcoxon signed-ranked test. Results: In total, 545 patients were included for the 2-y PFS classification and 561 for survival analysis. Clinical features alone, consolidation features alone, conventional PET features, and RFs extracted at patient level achieved an AUC of, respectively, 0.65 ± 0.07, 0.64 ± 0.06, 0.60 ± 0.07, and 0.62 ± 0.07 (0.62 ± 0.07 for the largest lesion and 0.54 ± 0.07 for the hottest). Combining clinical features with the consolidation features led to the best AUC (0.72 ± 0.06). Adding conventional PET features or RFs did not improve the results. For survival, the log-rank P values of the model involving clinical and consolidation features together were significantly smaller than all combined-feature groups (P < 0.007). Conclusion: The results showed that a concatenation of multimodal features coupled with a simple machine-learning model does not seem to improve the results in terms of 2-y PFS classification and PFS prediction for patient treated according to the GAINED protocol.
Collapse
Affiliation(s)
- Thomas Carlier
- Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France
- Nuclear Medicine Department, University Hospital, Nantes, France
| | - Gauthier Frécon
- Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France
- Nuclear Medicine Department, University Hospital, Nantes, France
| | - Diana Mateus
- Laboratoire des Sciences Numériques de Nantes, Ecole Centrale de Nantes, CNRS UMR 6004, Nantes, France
| | - Mira Rizkallah
- Laboratoire des Sciences Numériques de Nantes, Ecole Centrale de Nantes, CNRS UMR 6004, Nantes, France
| | - Françoise Kraeber-Bodéré
- Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France
- Nuclear Medicine Department, University Hospital, Nantes, France
| | - Salim Kanoun
- Nuclear Medicine, Georges-François Leclerc Center, Dijon, France
| | - Paul Blanc-Durand
- Nuclear Medicine, CHU Henri Mondor, Paris-Est University, Créteil, France
| | - Emmanuel Itti
- Nuclear Medicine, CHU Henri Mondor, Paris-Est University, Créteil, France
| | - Steven Le Gouill
- Haematology Department, University Hospital, Nantes, France; and
| | | | - Caroline Bodet-Milin
- Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France
- Nuclear Medicine Department, University Hospital, Nantes, France
| | - Clément Bailly
- Nantes Université, INSERM, CNRS, CRCINA, Université d'Angers, Nantes, France;
- Nuclear Medicine Department, University Hospital, Nantes, France
| |
Collapse
|
4
|
Bodet-Milin C, Morvant C, Carlier T, Frecon G, Tournilhac O, Safar V, Kraeber-Bodere F, Le Gouill S, Macintyre E, Bailly C. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial. Sci Rep 2023; 13:18177. [PMID: 37875524 PMCID: PMC10598231 DOI: 10.1038/s41598-023-45215-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 10/17/2023] [Indexed: 10/26/2023] Open
Abstract
The prognostic value of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at baseline or the predictive value of minimal residual disease (MRD) detection appear as potential tools to improve mantle cell lymphoma (MCL) patients' management. The LyMa-101, a phase 2 trial of the LYSA group (ClinicalTrials.gov:NCT02896582) reported induction therapy with obinutuzumab, a CD20 monoclonal antibody. Herein, we investigated the added prognostic value of radiomic features (RF) derived from FDG-PET/CT at diagnosis for MRD value prediction. FDG-PET/CT of 59 MCL patients included in the LyMa-101 trial have been independently, blindly and centrally reviewed. RF were extracted from the disease area with the highest uptake and from the total metabolic tumor volume (TMTV). Two models of machine learning were used to compare several combinations for prediction of MRD before autologous stem cell transplant consolidation (ASCT). Each algorithm was generated with or without constrained feature selections for clinical and laboratory parameters. Both algorithms showed better discrimination performances for negative vs positive MRD in the lesion with the highest uptake than in the TMTV. The constrained use of clinical and biological features showed a clear loss in sensitivity for the prediction of MRD status before ASCT, regardless of the machine learning model. These data plead for the importance of FDG-PET/CT RF compared to clinical and laboratory parameters and also reinforced the previously made hypothesis that the prognosis of the disease in MCL patients is linked to the most aggressive contingent, within the lesion with the highest uptake.
Collapse
Affiliation(s)
- Caroline Bodet-Milin
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France
| | - Cyrille Morvant
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France
| | - Thomas Carlier
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France
| | - Gauthier Frecon
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France
| | - Olivier Tournilhac
- Haematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Violaine Safar
- Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France
| | - Françoise Kraeber-Bodere
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France
| | - Steven Le Gouill
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France
- Institut Curie, Paris and Saint-Cloud, Université Versailles-Saint Quentin, Saint-Cloud, France
| | - Elizabeth Macintyre
- Onco-Haematology, Université de Paris, Hôpital and Institut Necker-Enfants Malades, Assistance-Publique-Hôpitaux de Paris, INSERM U1151, Paris, France
| | - Clément Bailly
- Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
- Nuclear Medicine Unit, University Hospital, 44093, Nantes, France.
| |
Collapse
|
5
|
Godefroy T, Frécon G, Asquier-Khati A, Mateus D, Lecomte R, Rizkallah M, Piriou N, Jamet B, Le Tourneau T, Pallardy A, Boutoille D, Eugène T, Carlier T. 18F-FDG-Based Radiomics and Machine Learning: Useful Help for Aortic Prosthetic Valve Infective Endocarditis Diagnosis? JACC Cardiovasc Imaging 2023:S1936-878X(23)00093-1. [PMID: 37052569 DOI: 10.1016/j.jcmg.2023.01.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 01/25/2023] [Indexed: 04/14/2023]
Abstract
BACKGROUND Fluorine-18 fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) results in better sensitivity for prosthetic valve endocarditis (PVE) diagnosis, but visual image analysis results in relatively weak specificity and significant interobserver variability. OBJECTIVES The primary objective of this study was to evaluate the performance of a radiomics and machine learning-based analysis of 18F-FDG PET/CT (PET-ML) as a major criterion for the European Society of Cardiology score using machine learning as a major imaging criterion (ESC-ML) in PVE diagnosis. The secondary objective was to assess performance of PET-ML as a standalone examination. METHODS All 18F-FDG-PET/CT scans performed for suspected aortic PVE at a single center from 2015 to 2021 were retrospectively included. The gold standard was expert consensus after at least 3 months' follow-up. The machine learning (ML) method consisted of manually segmenting each prosthetic valve, extracting 31 radiomics features from the segmented region, and training a ridge logistic regressor to predict PVE. Training and hyperparameter tuning were done with a cross-validation approach, followed by an evaluation on an independent test database. RESULTS A total of 108 patients were included, regardless of myocardial uptake, and were divided into training (n = 68) and test (n = 40) cohorts. Considering the latter, PET-ML findings were positive for 13 of 22 definite PVE cases and 3 of 18 rejected PVE cases (59% sensitivity, 83% specificity), thus leading to an ESC-ML sensitivity of 72% and a specificity of 83%. CONCLUSIONS The use of ML for analyzing 18F-FDG-PET/CT images in PVE diagnosis was feasible and beneficial, particularly when ML was included in the ESC 2015 criteria. Despite some limitations and the need for future developments, this approach seems promising to optimize the role of 18F-FDG PET/CT in PVE diagnosis.
Collapse
Affiliation(s)
- Thomas Godefroy
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France
| | - Gauthier Frécon
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France; ECN, LS2N, Nantes, France
| | - Antoine Asquier-Khati
- Nantes Université, CHU Nantes, INSERM, Infectious Diseases Department, Nantes, France
| | | | - Raphaël Lecomte
- Nantes Université, CHU Nantes, INSERM, Infectious Diseases Department, Nantes, France
| | | | - Nicolas Piriou
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, Nantes, France
| | - Bastien Jamet
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France
| | - Thierry Le Tourneau
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, Nantes, France
| | - Amandine Pallardy
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France
| | - David Boutoille
- Nantes Université, CHU Nantes, INSERM, Infectious Diseases Department, Nantes, France
| | - Thomas Eugène
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France.
| | - Thomas Carlier
- Nantes Université, CHU Nantes, INSERM, Nuclear Médicine, Nantes, France
| |
Collapse
|
6
|
Li C, Wang S, Li C, Yin Y, Feng F, Fu H, Wang H, Chen S. Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma. Front Oncol 2022; 12:896593. [PMID: 36353561 PMCID: PMC9637983 DOI: 10.3389/fonc.2022.896593] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 09/20/2022] [Indexed: 11/12/2023] Open
Abstract
PURPOSE The substratification of high-risk neuroblastoma is challenging, and new predictive imaging biomarkers are warranted for better patient selection. The aim of the study was to evaluate the prognostic role of PET-based intratumor heterogeneity and its potential ability to improve risk stratification in neuroblastoma. METHODS Pretreatment 18F-FDG PET/CT scans from 112 consecutive children with newly diagnosed neuroblastoma were retrospectively analyzed. The primary tumor was segmented in the PET images. SUVs, volumetric parameters including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), and texture features were extracted. After the exclusion of imaging features with poor and moderate reproducibility, the relationships between the imaging indices and clinicopathological factors, as well as event-free survival (EFS), were assessed. RESULTS The median follow-up duration was 33 months. Multivariate analysis showed that PET-based intratumor heterogeneity outperformed clinicopathological features, including age, stage, and MYCN, and remained the most robust independent predictor for EFS [training set, hazard ratio (HR): 6.4, 95% CI: 3.1-13.2, p < 0.001; test set, HR: 5.0, 95% CI: 1.8-13.6, p = 0.002]. Within the clinical high-risk group, patients with a high metabolic heterogeneity showed significantly poorer outcomes (HR: 3.3, 95% CI: 1.6-6.8, p = 0.002 in the training set; HR: 4.4, 95% CI: 1.5-12.9, p = 0.008 in the test set) compared to those with relatively homogeneous tumors. Furthermore, intratumor heterogeneity outran the volumetric indices (MTVs and TLGs) and yielded the best performance of distinguishing high-risk patients with different outcomes with a 3-year EFS of 6% vs. 47% (p = 0.001) in the training set and 9% vs. 51% (p = 0.004) in the test set. CONCLUSION PET-based intratumor heterogeneity was a strong independent prognostic factor in neuroblastoma. In the clinical high-risk group, intratumor heterogeneity further stratified patients with distinct outcomes.
Collapse
Affiliation(s)
- Chao Li
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Shaoyan Wang
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Can Li
- Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yafu Yin
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Fang Feng
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hongliang Fu
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hui Wang
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Suyun Chen
- Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
7
|
Paquier Z, Chao SL, Acquisto A, Fenton C, Guiot T, Dhont J, Levillain H, Gulyban A, Bali MA, Reynaert N. Radiomics software comparison using digital phantom and patient data: IBSI-compliance does not guarantee concordance of feature values. Biomed Phys Eng Express 2022; 8. [PMID: 36049399 DOI: 10.1088/2057-1976/ac8e6f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 09/01/2022] [Indexed: 11/12/2022]
Abstract
Introduction Radiomics is a promising imaging-based tool which could enhance clinical observation and identify representative features. To avoid different interpretations, the Image Biomarker Standardisation Initiative (IBSI) imposed conditions for harmonisation. This study evaluates IBSI-compliant radiomics applications against a known benchmark and clinical datasets for agreements. Materials and methods The applications compared were RadiomiX Research Toolbox, LIFEx v7.0.0, and syngo.via Frontier Radiomics v1.2.5 (based on PyRadiomics v2.1). Basic assessment included comparing feature names and their formulas. The IBSI digital phantom was used for evaluation against reference values. For agreement evaluation (including same software but different versions), two clinical datasets were used: 27 contrast-enhanced computed tomography (CECT) of colorectal liver metastases and 39 magnetic resonance imaging (MRI) of breast cancer, including intravoxel incoherent motion and dynamic contrast-enhanced (DCE) MRI. The lower 95% confidence interval of intraclass correlation coefficient was used to define excellent agreement (>0.9). Results The three radiomics applications share 41 (3 shape, 8 intensity, 30 texture) out of 172, 84 and 110 features for RadiomiX, LIFEx and syngo.via, respectively, as well as wavelet filtering. The naming convention is, however, different between them. Syngo.via had excellent agreement with the IBSI benchmark, while LIFEx and RadiomiX showed slightly worse agreement. Excellent reproducibility was achieved for shape features only, while intensity and texture features varied considerably with the imaging type. For intensity, excellent agreement ranged from 46% for the DCE maps to 100% for CECT, while this lowered to 44% and 73% for texture features, respectively. Wavelet features produced the greatest variation between applications, with an excellent agreement for only 3% to 11% features. Conclusion Even with IBSI-compliance, the reproducibility of features between radiomics applications is not guaranteed. To evaluate variation, quality assurance of radiomics applications should be performed and repeated when updating to a new version or adding a new modality.
Collapse
Affiliation(s)
- Zelda Paquier
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Shih-Li Chao
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Anaïs Acquisto
- Radiology, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Chifra Fenton
- Radiology, Erasmus Hospital, Rte de Lennik 808, Bruxelles, 1070, BELGIUM
| | - Thomas Guiot
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Jennifer Dhont
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Hugo Levillain
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | - Akos Gulyban
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| | | | - Nick Reynaert
- Medical Physics, Institut Jules Bordet, Rue Meylemeersch 90, Bruxelles, 1070, BELGIUM
| |
Collapse
|
8
|
Bradshaw TJ, Boellaard R, Dutta J, Jha AK, Jacobs P, Li Q, Liu C, Sitek A, Saboury B, Scott PJH, Slomka PJ, Sunderland JJ, Wahl RL, Yousefirizi F, Zuehlsdorff S, Rahmim A, Buvat I. Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development. J Nucl Med 2022; 63:500-510. [PMID: 34740952 PMCID: PMC10949110 DOI: 10.2967/jnumed.121.262567] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 11/01/2021] [Indexed: 11/16/2022] Open
Abstract
The nuclear medicine field has seen a rapid expansion of academic and commercial interest in developing artificial intelligence (AI) algorithms. Users and developers can avoid some of the pitfalls of AI by recognizing and following best practices in AI algorithm development. In this article, recommendations on technical best practices for developing AI algorithms in nuclear medicine are provided, beginning with general recommendations and then continuing with descriptions of how one might practice these principles for specific topics within nuclear medicine. This report was produced by the AI Task Force of the Society of Nuclear Medicine and Molecular Imaging.
Collapse
Affiliation(s)
- Tyler J Bradshaw
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin;
| | - Ronald Boellaard
- Department of Radiology and Nuclear Medicine, Cancer Centre Amsterdam, Amsterdam University Medical Centres, Amsterdam, The Netherlands
| | - Joyita Dutta
- Department of Electrical and Computer Engineering, University of Massachusetts Lowell, Lowell, Massachusetts
| | - Abhinav K Jha
- Department of Biomedical Engineering and Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri
| | | | - Quanzheng Li
- Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| | - Chi Liu
- Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut
| | | | - Babak Saboury
- Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland
| | - Peter J H Scott
- Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan
| | - Piotr J Slomka
- Department of Imaging, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, California
| | - John J Sunderland
- Departments of Radiology and Physics, University of Iowa, Iowa City, Iowa
| | - Richard L Wahl
- Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri
| | - Fereshteh Yousefirizi
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada
| | | | - Arman Rahmim
- Departments of Radiology and Physics, University of British Columbia, Vancouver, British Columbia, Canada; and
| | - Irène Buvat
- Institut Curie, Université PSL, INSERM, Université Paris-Saclay, Orsay, France
| |
Collapse
|
9
|
de Vries BM, Golla SSV, Zwezerijnen GJC, Hoekstra OS, Jauw YWS, Huisman MC, van Dongen GAMS, Menke-van der Houven van Oordt WC, Zijlstra-Baalbergen JJM, Mesotten L, Boellaard R, Yaqub M. 3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. Diagnostics (Basel) 2022; 12:diagnostics12030596. [PMID: 35328149 PMCID: PMC8946936 DOI: 10.3390/diagnostics12030596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 02/22/2022] [Accepted: 02/24/2022] [Indexed: 11/23/2022] Open
Abstract
Acquisition time and injected activity of 18F-fluorodeoxyglucose (18F-FDG) PET should ideally be reduced. However, this decreases the signal-to-noise ratio (SNR), which impairs the diagnostic value of these PET scans. In addition, 89Zr-antibody PET is known to have a low SNR. To improve the diagnostic value of these scans, a Convolutional Neural Network (CNN) denoising method is proposed. The aim of this study was therefore to develop CNNs to increase SNR for low-count 18F-FDG and 89Zr-antibody PET. Super-low-count, low-count and full-count 18F-FDG PET scans from 60 primary lung cancer patients and full-count 89Zr-rituximab PET scans from five patients with non-Hodgkin lymphoma were acquired. CNNs were built to capture the features and to denoise the PET scans. Additionally, Gaussian smoothing (GS) and Bilateral filtering (BF) were evaluated. The performance of the denoising approaches was assessed based on the tumour recovery coefficient (TRC), coefficient of variance (COV; level of noise), and a qualitative assessment by two nuclear medicine physicians. The CNNs had a higher TRC and comparable or lower COV to GS and BF and was also the preferred method of the two observers for both 18F-FDG and 89Zr-rituximab PET. The CNNs improved the SNR of low-count 18F-FDG and 89Zr-rituximab PET, with almost similar or better clinical performance than the full-count PET, respectively. Additionally, the CNNs showed better performance than GS and BF.
Collapse
Affiliation(s)
- Bart M. de Vries
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Correspondence: ; Tel.: +31-643628806
| | - Sandeep S. V. Golla
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Gerben J. C. Zwezerijnen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Otto S. Hoekstra
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Yvonne W. S. Jauw
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Cancer Center Amsterdam, Department of Hematology, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Marc C. Huisman
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Guus A. M. S. van Dongen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | | | - Josée J. M. Zijlstra-Baalbergen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Cancer Center Amsterdam, Department of Hematology, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Liesbet Mesotten
- Faculty of Medicine and Life Sciences, Hasselt University, Agoralaan Building D, B-3590 Diepenbeek, Belgium;
- Department of Nuclear Medicine, Ziekenhuis Oost Limburg, Schiepse Bos 6, B-3600 Genk, Belgium
| | - Ronald Boellaard
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Maqsood Yaqub
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| |
Collapse
|
10
|
Anan N, Zainon R, Tamal M. A review on advances in 18F-FDG PET/CT radiomics standardisation and application in lung disease management. Insights Imaging 2022; 13:22. [PMID: 35124733 PMCID: PMC8817778 DOI: 10.1186/s13244-021-01153-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 12/23/2021] [Indexed: 02/06/2023] Open
Abstract
Radiomics analysis quantifies the interpolation of multiple and invisible molecular features present in diagnostic and therapeutic images. Implementation of 18-fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) radiomics captures various disorders in non-invasive and high-throughput manner. 18F-FDG PET/CT accurately identifies the metabolic and anatomical changes during cancer progression. Therefore, the application of 18F-FDG PET/CT in the field of oncology is well established. Clinical application of 18F-FDG PET/CT radiomics in lung infection and inflammation is also an emerging field. Combination of bioinformatics approaches or textual analysis allows radiomics to extract additional information to predict cell biology at the micro-level. However, radiomics texture analysis is affected by several factors associated with image acquisition and processing. At present, researchers are working on mitigating these interrupters and developing standardised workflow for texture biomarker establishment. This review article focuses on the application of 18F-FDG PET/CT in detecting lung diseases specifically on cancer, infection and inflammation. An overview of different approaches and challenges encountered on standardisation of 18F-FDG PET/CT technique has also been highlighted. The review article provides insights about radiomics standardisation and application of 18F-FDG PET/CT in lung disease management.
Collapse
|
11
|
Orlhac F, Nioche C, Klyuzhin I, Rahmim A, Buvat I. Radiomics in PET Imaging:: A Practical Guide for Newcomers. PET Clin 2021; 16:597-612. [PMID: 34537132 DOI: 10.1016/j.cpet.2021.06.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Radiomics has undergone considerable development in recent years. In PET imaging, very promising results concerning the ability of handcrafted features to predict the biological characteristics of lesions and to assess patient prognosis or response to treatment have been reported in the literature. This article presents a checklist for designing a reliable radiomic study, gives an overview of the steps of the pipeline, and outlines approaches for data harmonization. Tips are provided for critical reading of the content of articles. The advantages and limitations of handcrafted radiomics compared with deep-learning approaches for the characterization of PET images are also discussed.
Collapse
Affiliation(s)
- Fanny Orlhac
- Institut Curie Centre de Recherche, Centre Universitaire, Bat 101B, Rue Henri Becquerel, CS 90030, 91401 Orsay Cedex, France.
| | - Christophe Nioche
- Institut Curie Centre de Recherche, Centre Universitaire, Bat 101B, Rue Henri Becquerel, CS 90030, 91401 Orsay Cedex, France
| | - Ivan Klyuzhin
- Department of Integrative Oncology, BC Cancer Research Institute, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
| | - Arman Rahmim
- Department of Integrative Oncology, BC Cancer Research Institute, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
| | - Irène Buvat
- Institut Curie Centre de Recherche, Centre Universitaire, Bat 101B, Rue Henri Becquerel, CS 90030, 91401 Orsay Cedex, France
| |
Collapse
|
12
|
Carles M, Fechter T, Martí-Bonmatí L, Baltas D, Mix M. Experimental phantom evaluation to identify robust positron emission tomography (PET) radiomic features. EJNMMI Phys 2021; 8:46. [PMID: 34117929 PMCID: PMC8197692 DOI: 10.1186/s40658-021-00390-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 05/12/2021] [Indexed: 12/14/2022] Open
Abstract
Background Radiomics analysis usually involves, especially in multicenter and large hospital studies, different imaging protocols for acquisition, reconstruction, and processing of data. Differences in protocols can lead to differences in the quantification of the biomarker distribution, leading to radiomic feature variability. The aim of our study was to identify those radiomic features robust to the different degrading factors in positron emission tomography (PET) studies. We proposed the use of the standardized measurements of the European Association Research Ltd. (EARL) accreditation to retrospectively identify the radiomic features having low variability to the different systems and reconstruction protocols. In addition, we presented a reproducible procedure to identify PET radiomic features robust to PET/CT imaging metal artifacts. In 27 heterogeneous homemade phantoms for which ground truth was accurately defined by CT segmentation, we evaluated the segmentation accuracy and radiomic feature reliability given by the contrast-oriented algorithm (COA) and the 40% threshold PET segmentation. In the comparison of two data sets, robustness was defined by Wilcoxon rank tests, bias was quantified by Bland–Altman (BA) plot analysis, and strong correlations were identified by Spearman correlation test (r > 0.8 and p satisfied multiple test Bonferroni correction). Results Forty-eight radiomic features were robust to system, 22 to resolution, 102 to metal artifacts, and 42 to different PET segmentation tools. Overall, only 4 radiomic features were simultaneously robust to all degrading factors. Although both segmentation approaches significantly underestimated the volume with respect to the ground truth, with relative deviations of −62 ± 36% for COA and −50 ± 44% for 40%, radiomic features derived from the ground truth were strongly correlated and/or robust to 98 radiomic features derived from COA and to 102 from 40%. Conclusion In multicenter studies, we recommend the analysis of EARL accreditation measurements in order to retrospectively identify the robust PET radiomic features. Furthermore, 4 radiomic features (area under the curve of the cumulative SUV volume histogram, skewness, kurtosis, and gray-level variance derived from GLRLM after application of an equal probability quantization algorithm on the voxels within lesion) were robust to all degrading factors. In addition, the feasibility of 40% and COA segmentations for their use in radiomics analysis has been demonstrated. Supplementary Information The online version contains supplementary material available at 10.1186/s40658-021-00390-7.
Collapse
Affiliation(s)
- Montserrat Carles
- Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany. .,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany. .,Biomedical Imaging Research Group (GIBI230-PREBI) and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
| | - Tobias Fechter
- Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Luis Martí-Bonmatí
- Biomedical Imaging Research Group (GIBI230-PREBI) and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), La Fe Health Research Institute, Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain
| | - Dimos Baltas
- Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Mix
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.,Department of Medical Imaging and Clinical Oncology, Nuclear Medicine Division, Faculty of Medicine and Health Science, Stellenbosch University, Stellenbosch, South Africa
| |
Collapse
|